Evidence map›Paper›PMID 37996972›Full record

ArticleCancer science2024

Identification of target cells of human papillomavirus 18 using squamocolumnar junction organoids.

Yusuke Toyohara, Ayumi Taguchi, Yoshiyuki Ishii, Daisuke Yoshimoto, Miki Yamazaki, Hiroko Matsunaga, Kazuma Nakatani, Daisuke Hoshi, Saki Tsuchimochi, Misako Kusakabe and 12 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Three-DimensionalInternational journal of biological sciences · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Yusuke ToyoharaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ayumi TaguchiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5491-3871
Yoshiyuki IshiiPathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan.
Daisuke YoshimotoDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Miki YamazakiDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.
Hiroko MatsunagaResearch organization for Nano and Life Innovation, Waseda University, Tokyo, Japan.
Kazuma NakataniDepartment of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.
Daisuke HoshiDepartment of Oncologic Pathology, Kanazawa Medical University, Uchinada, Japan.
Saki TsuchimochiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Misako KusakabeDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Satoshi BabaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Akira KawataDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masako IkemuraDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Michihiro TanikawaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenbun SoneDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7218-6401
Mayuyo Uchino-MoriDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tetsuo UshikuDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Haruko TakeyamaDepartment of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.
Katsutoshi OdaDepartment of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kei KawanaDepartment of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.
Yoshitaka HippoDepartment of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan.ORCID https://orcid.org/0000-0002-4975-1812
Yutaka OsugaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPWaseda University · JPChiba Cancer Center · JPKanazawa Medical University · JPNational Institute of Infectious Diseases · JPNihon University · JPOsaka International University · JP

Funding

Japan Agency for Medical Research and Development 22wm0325014h0003Japan Agency for Medical Research and Development 23wm0325057h0001Japan Agency for Medical Research and Development JP21am0101104Japan Agency for Medical Research and Development JP22ama121055Japan Society for the Promotion of Science 20K18157Japan Society for the Promotion of Science 22K16853
6 · The paper itself

Abstract

Human papillomavirus 18 (HPV18) is a highly malignant HPV genotype among high-risk HPVs, characterized by the difficulty of detecting it in precancerous lesions and its high prevalence in adenocarcinomas. The cellular targets and molecular mechanisms underlying its infection remain unclear. In this study, we aimed to identify the cells targeted by HPV18 and elucidate the molecular mechanisms underlying HPV18 replication. Initially, we established a lentiviral vector (HPV18LCR-GFP vector) containing the HPV18 long control region promoter located upstream of EGFP. Subsequently, HPV18LCR-GFP vectors were transduced into patient-derived squamocolumnar junction organoids, and the presence of GFP-positive cells was evaluated. Single-cell RNA sequencing of GFP-positive and GFP-negative cells was conducted. Differentially expressed gene analysis revealed that 169 and 484 genes were significantly upregulated in GFP-positive and GFP-negative cells, respectively. Pathway analysis showed that pathways associated with cell cycle and viral carcinogenesis were upregulated in GFP-positive cells, whereas keratinization and mitophagy/autophagy-related pathways were upregulated in GFP-negative cells. siRNA-mediated luciferase reporter assay and HPV18 genome replication assay validated that, among the upregulated genes, ADNP, FHL2, and NPM3 were significantly associated with the activation of the HPV18 early promoter and maintenance of the HPV18 genome. Among them, NPM3 showed substantially higher expression in HPV-related cervical adenocarcinomas than in squamous cell carcinomas, and NPM3 knockdown of HPV18-infected cells downregulated stem cell-related genes. Our new experimental model allows us to identify novel genes involved in HPV18 early promoter activities. These molecules might serve as therapeutic targets in HPV18-infected cervical lesions.

Indexed as

AdenocarcinomaPapillomavirus InfectionsUterine Cervical NeoplasmsFemaleHuman papillomavirus 18HumansOrganoidshuman papillomaviruslong control regionorganoid culturesquamocolumnar junctionuterine cervical cancer

Identifiers

PMID37996972
PMCPMC10823277
OpenAlexW4388982137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.